论文部分内容阅读
目的探讨伊立替康(CPT-11)+洛铂联合重组人血管内皮抑制素注射液治疗晚期复发小细胞肺癌(SCLC)的临床疗效。方法选取2012年7月至2014年7月间新疆维吾尔自治区人民医院收治的68例晚期复发SCLC患者,采用随机数字表法分为观察组(37例)和对照组(31例)。观察组患者接受CPT-11+洛铂联合重组人血管内皮抑制素注射液治疗,对照组患者接受CPT-11+洛铂治疗方案,观察并比较两组患者的疗效。结果观察组患者总有效率为59.5%,对照组为48.4%,组间差异无统计学意义(P>0.05)。两组患者均有不良反应发生,且大都可以耐受,观察组患者白细胞下降和肝功能异常的发生率明显降低。观察组和对照组的中位无进展生存期(PFS)分别为8个月(95%CI为2.7~12.1)和5个月(95%CI为2.1~6.3),组间差异无统计学意义(P=0.07)。观察组和对照组的总生存期(OS)分别为11.2个月(95%CI为0.9~52.6)和6.4个月(95%CI为7.8~16.9),组间差异有统计学意义(P=0.04)。结论 CPT-11+洛铂联合重组人血管内皮抑制素注射液治疗晚期复发小细胞肺癌的临床疗效较好,不良反应发生率较低,且可以延长患者的生存时间。
Objective To investigate the clinical efficacy of irinotecan (CPT-11) plus lobaplatin combined with recombinant human endostatin injection in the treatment of advanced recurrent small cell lung cancer (SCLC). Methods Sixty - eight patients with advanced recurrent SCLC who were admitted to People ’s Hospital of Xinjiang Uigur Autonomous Region between July 2012 and July 2014 were divided into observation group (37 cases) and control group (31 cases) by random number table. Patients in the observation group received CPT-11 + lobaplatin combined with recombinant human endostatin injection, and patients in the control group received CPT-11 + lobaplatin treatment. The therapeutic effect was observed and compared between the two groups. Results The total effective rate was 59.5% in the observation group and 48.4% in the control group, with no significant difference between the two groups (P> 0.05). Adverse reactions occurred in both groups, and most of them were tolerable. The incidence of leukopenia and abnormal liver function in observation group was significantly lower. The median progression-free survival (PFS) in observation and control groups was 8 months (95% CI, 2.7-12.1) and 5 months (95% CI, 2.1-6.3), respectively, with no significant difference between groups (P = 0.07). The overall survival (OS) was 11.2 months (95% CI, 0.9 to 52.6) and 6.4 months (95% CI, 7.8 to 16.9) in the observation and control groups, respectively. There was significant difference between the two groups (P = 0.04). Conclusions CPT-11 + lobaplatin combined with recombinant human endostatin injection for the treatment of advanced recurrent small cell lung cancer has good clinical efficacy, low incidence of adverse reactions, and can prolong the survival time of patients.